Background: Rosiglitazone and pioglitazone may increase the incidence of fractures. We
aimed to determine systematically the risk of fractures associated with thiazolidinedione …

Diabet. Med. 28, 759–771 (2011) Abstract Thiazolidinediones are widely used effective
drugs for the management of hyperglycaemia in Type 2 diabetes and may provide additional …

Aim: The objectives of the study were to determine whether thiazolidinedione (TZD) use is
associated with an increased risk of fracture in men and women with type 2 diabetes mellitus …

Context: Thiazolidinedione (TZD) use has recently been associated with an increased risk of
fractures. Objective: The aim of this study was to determine the time-dependent relationship …

Background The results of clinical trials have suggested that the thiazolidinedione
antidiabetic agents rosiglitazone and pioglitazone are associated with an increased risk of …

Background: Thiazolidinedione (TZD) treatment has been associated with fractures. The
purpose of this study was to examine the association between TZD treatment and fractures …

Background Clinical trials and meta-analyses have found that rosiglitazone maleate, a
thiazolidinedione that is prescribed for type 2 diabetes mellitus, increases the risk of …

Background Thiazolidinediones may adversely affect the skeleton owing to decreased bone
formation and accelerated bone loss. Methods This study examines the association between …

Context: Thiazolidenediones (TZDs) are selective ligands of peroxisome-proliferator-
activated receptor-γ and have been shown to reduce bone mineral density. Recent results …

OBJECTIVE—The purpose of this study was to examine possible factors associated with the
increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression …